comprehensive -WSS

comprehensive

author：fashion 2025-10-02 14:57:19 - browse：24

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： FDA needs staff influx to meet gene therapy needs, Marks says

focus

leisure time

WSS

Pharma patents targeted by Biden in move to slash drug prices

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Patients' immediate access to test results puts radiologists in a bind

CMS should re

AI models in health care face new federal disclosure requirements

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

entertainment

comprehensive

Wikipedia

In age of alternative facts, a scholarly course on calling out crap

Getting Alzheimer's drug Leqembi to patients can be a challenge

Duchenne breakthrough therapy leaves behind pioneering families

CMS should re

ChatGPT in medicine: STAT answers readers' burning questions

After sickle

Jerome Adams on the need for new antivirals for Covid

Pregnancy discrimination could be enabled by AI

Drug repurposing or repositioning? The language matters

After traumatic brain injury, life support decisions can use more time

hotspot

Congenital heart disease patients face new threat of heart failure

Bird flu in milk supply is likely coming from asymptomatic cows

Cholera vaccine supply gets boost as demand surges globally

Melinda French Gates resigns from Gates Foundation

AI models in health care face new federal disclosure requirements

The woman behind the Dana Farber

focus

leisure time

focus

leisure time